中华胃肠外科杂志
中華胃腸外科雜誌
중화위장외과잡지
CHINESE JOURNAL OF GASTROINTESTINAL SURGERY
2011年
11期
896-898
,共3页
结肠肿瘤%肿瘤干细胞%抗原,CD133%抗原,CD44%上皮表面抗原
結腸腫瘤%腫瘤榦細胞%抗原,CD133%抗原,CD44%上皮錶麵抗原
결장종류%종류간세포%항원,CD133%항원,CD44%상피표면항원
Colonic neoplasms%Tumor stem cells%Antigens,CD133%Antigens,CD44%Epithelial surface antigen
目的 分选结肠癌细胞株SW480细胞中的CD133+-CD44+-ESA+亚群细胞,并观察其致瘤性.方法 用流式细胞仪分选SW480细胞中CD133+-CD44+-ESA+、CD133--CD44+-ESA+及CD133--CD44--ESA-亚群细胞.将这3组细胞分别接种于NOD/SCID小鼠,每组5只,观察肿瘤生长情况.结果 SW480细胞中CD133--CD44--ESA-、CD133--CD44+-ESA+和CD133+-CD44+-ESA+亚群细胞分别占(86.38±10.23)％、(1.26±0.28)％和(0.38±0.07)％.接种3d后,CD 133+-CD44+-ESA+细胞组小鼠可形成瘤结节；CD133--CD44+-ESA+细胞组小鼠9d左右可见瘤结节,而CD133--CD44--ESA-细胞组小鼠则要到15 d方可见瘤结节.接种后18d,3组小鼠肿瘤大小分别为(13.82±5.04)mm3、(9.25±4.57)mm3和(4.76±3.92) mm3,差异有统计学意义(P＜0.05).结论 CD44+-ESA+是结肠癌干细胞表面标记之一；CD 133+-CD44+-ESA+细胞则是SW480细胞的癌干样细胞.
目的 分選結腸癌細胞株SW480細胞中的CD133+-CD44+-ESA+亞群細胞,併觀察其緻瘤性.方法 用流式細胞儀分選SW480細胞中CD133+-CD44+-ESA+、CD133--CD44+-ESA+及CD133--CD44--ESA-亞群細胞.將這3組細胞分彆接種于NOD/SCID小鼠,每組5隻,觀察腫瘤生長情況.結果 SW480細胞中CD133--CD44--ESA-、CD133--CD44+-ESA+和CD133+-CD44+-ESA+亞群細胞分彆佔(86.38±10.23)％、(1.26±0.28)％和(0.38±0.07)％.接種3d後,CD 133+-CD44+-ESA+細胞組小鼠可形成瘤結節；CD133--CD44+-ESA+細胞組小鼠9d左右可見瘤結節,而CD133--CD44--ESA-細胞組小鼠則要到15 d方可見瘤結節.接種後18d,3組小鼠腫瘤大小分彆為(13.82±5.04)mm3、(9.25±4.57)mm3和(4.76±3.92) mm3,差異有統計學意義(P＜0.05).結論 CD44+-ESA+是結腸癌榦細胞錶麵標記之一；CD 133+-CD44+-ESA+細胞則是SW480細胞的癌榦樣細胞.
목적 분선결장암세포주SW480세포중적CD133+-CD44+-ESA+아군세포,병관찰기치류성.방법 용류식세포의분선SW480세포중CD133+-CD44+-ESA+、CD133--CD44+-ESA+급CD133--CD44--ESA-아군세포.장저3조세포분별접충우NOD/SCID소서,매조5지,관찰종류생장정황.결과 SW480세포중CD133--CD44--ESA-、CD133--CD44+-ESA+화CD133+-CD44+-ESA+아군세포분별점(86.38±10.23)％、(1.26±0.28)％화(0.38±0.07)％.접충3d후,CD 133+-CD44+-ESA+세포조소서가형성류결절；CD133--CD44+-ESA+세포조소서9d좌우가견류결절,이CD133--CD44--ESA-세포조소서칙요도15 d방가견류결절.접충후18d,3조소서종류대소분별위(13.82±5.04)mm3、(9.25±4.57)mm3화(4.76±3.92) mm3,차이유통계학의의(P＜0.05).결론 CD44+-ESA+시결장암간세포표면표기지일；CD 133+-CD44+-ESA+세포칙시SW480세포적암간양세포.
Objective To isolate CD133+/CD44+/ESA+ subsets cells from SW480 colon cancer cells,and to observe the tumor formation.Method CD133+/CD44+/ESA+ subsets cells,CD133-/CD44+/ESA+ subsets cells and CD133-/CD44-/ESA- subsets cell were sorted by flow cytometry from SW480 colon cancer cells,then three subsets were separately inoculated in five NOD/SCID mice and thegrowth rates were calculated.Result The proportion of CD133-/CD44-/ESA-,CD133-/CD44+/ESA+ and CD133+/CD44+/ESA+ subsets cells in SW480 cells were (86.38±10.23)％,(1.26±0.28)％ and (0.38±0.07)％.After inoculation,tumor nodules could be formed three days later in CD133+/CD44+/ESA+group,and they could be formed 9 days later in CD133-/CD44+/ESA+ group,while they could be formed 15 days later in CD133-/CD44-/ESA- group.Eighteen days later,tumor sizes in three groups were(13.82±5.04) mm3,(9.25±4.57) mm3 and (4.76±3.92) mm3 respectively,and the differences were statistically significant (P＜0.05).Conclusion ESA+-CD44+ is one of the surface markers for colonic cancer stem cells,and CD133+-CD44+-ESA+ cells are SW480-1ike cancer stem cells.
